Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2008) 16 P283

ECE2008 Poster Presentations Endocrine tumours (77 abstracts)

Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism in MEN-1 patients

Antongiulio Faggiano 1 , Lidice Tavares 1 , Francesco Milone 1 , Gelsomina Mansueto 2 , Valeria Ramundo 1 , Maria Laura Del Basso De Caro 2 , Gaetano Lombardi 1 , Gaetano De Rosa 2 & Annamaria Colao 1


1Federico Ii University, Departments of Molecular and Clinical Endocrinology and Oncology, Naples, Italy; 2Federico Ii University, Biomorphological and Functional Sciences, Naples, Italy.


Background: Expression of somatostatin receptor (SST) and therapy with somatostatin analogues have been scarcely investigated in parathyroid tumors.

Objective: To evaluate the effects of depot long acting octreotide (OCT-LAR) on primary hyperparathyroidism in patients affected with multiple endocrine neoplasia type 1 (MEN-1).

Subjects and methods: Eight patients with a genetically confirmed MEN-1 were enrolled. All patients presented with primary hyperparathyroidism together with duodeno-pancreatic neuroendocrine tumors. A SST scintigraphy was performed in all patients before therapy with OCT-LAR. OCT-LAR 30 mg was administered every 4 weeks in all patients. Effects of OCT-LAR therapy on serum PTH, serum and urinary calcium and phosphorus were evaluated for 6 months.

Results: OCT-LAR normalized hypercalcemia and hypercalciuria in 75% and 62.5% of patients, respectively, while serum PTH levels were significantly decreased but still above the normal range. At SST scintigraphy, a positive parathyroid tumor uptake was found in 37.5% of MEN1 patients. The decrease of both serum PTH and serum and urinary calcium levels after therapy with OCT-LAR occurred regardless from the SST scintigraphy results.

Conclusions: OCT-LAR controlled hypercalcemia and hypercalciuria associated with hyperparathyroidism in two thirds of patients with MEN1-related parathyroid adenomas. However, these effects seem to be dissociated by the suppression of PTH levels.

Article tools

My recent searches

No recent searches.